Search the Newsreel

Pharvaris (NASDAQ:PHVS) Reaches New 12-Month High - What's Next?

Pharvaris (NASDAQ:PHVS) recently hit a new 52-week high of $36.65, with a current market capitalization of $2.38 billion, despite missing its latest quarterly earnings estimate. Analyst sentiment is generally positive with a "Moderate Buy" consensus and an average price target of $50.08, though some …

Dimensional Fund Advisors LP Has $4.36 Million Stock Holdings in Varonis Systems, Inc. $VRNS

Dimensional Fund Advisors LP significantly increased its stake in Varonis Systems, Inc. (NASDAQ:VRNS) by 556% in the first quarter, now holding 203,037 shares valued at approximately $4.36 million. This move is part of broader institutional interest, with hedge funds owning 95.65% of the company. …

Quantinno Capital Management LP Has $1.65 Million Stock Holdings in Varonis Systems, Inc. $VRNS

Quantinno Capital Management LP significantly increased its stake in Varonis Systems, Inc. by 59% in Q1, bringing its total holdings to $1.65 million. Varonis Systems reported strong Q2 revenue and EPS that exceeded analyst expectations, though the company continues to operate with negative net …

AlTi Global (ALTI) Stock Drifts As AUM Climbs Yet Losses Linger

AlTi Global's stock saw a slight increase after its Q2 2026 earnings report, with assets under management (AUM) rising to US$49.7 billion due to net inflows. Despite this growth in AUM, the company continues to report losses, with a basic loss per share of …

How Record Q2 Results and the Vipal Deal At Savaria (TSX:SIS) Have Changed Its Investment Story

Benchmark raises Harvard Bioscience stock price target on revenue beat

Benchmark has increased its price target for Harvard Bioscience (NASDAQ:HBIO) to $7.50 from $6.00, maintaining a Speculative Buy rating after the company surpassed second-quarter revenue guidance. The company reported $22.7 million in revenue, exceeding both management's and consensus estimates, and subsequently raised its full-year …

Savara Inc 2Q 2026: Net loss $(40.2M), EPS $(0.16) — 10-Q Summary

Savara Inc reported a net loss of $(40.2M) and an EPS of $(0.16) for Q2 2026, widening its loss compared to the previous year. As a pre-revenue biopharma company, its financial highlights showed increased losses while business highlights focused on regulatory milestones, clinical progress …

Vardhman Special Steels vs Sunflag Iron and Steel: Share Price, PE and ROE Compared

How Investors Are Reacting To Savara (SVRA) Wider Q2 Loss And New US$108 Million Share Shelf

Savara Inc. reported a wider Q2 2026 net loss of US$40.23 million and filed a US$108.30 million shelf registration for common shares, primarily for an ESOP-related offering. Despite the financial losses and potential dilution, the company's investment narrative remains tied to upcoming regulatory decisions …

Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume - Here's What Happened

Pharvaris (NASDAQ:PHVS) experienced unusually high trading volume, with 487,339 shares traded, marking a 60% increase from the previous session. The stock closed at $34.48, and analysts maintain a "Moderate Buy" rating with an average price target of $50.08 despite the company missing quarterly EPS …

Pharvaris (NASDAQ:PHVS) Releases Earnings Results, Misses Expectations By $0.05 EPS

Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Aardvark Therapeutics reported its second-quarter 2026 financial results, highlighting $73.9 million in cash, cash equivalents, and short-term investments as of June 30, 2026, which is expected to fund operations into late 2027. The company is actively assessing unblinded Phase 3 HERO and OLE data …

Savara Inc. (SVRA) Advances 1.17% as Rare Disease Focus Draws Continued Interest — Resistance at $5.91 in Sight - Price Momentum Stocks

(PHVS) as a Liquidity Pulse for Institutional Tactics

This article provides a detailed AI-driven analysis of Pharvaris N.v. (NASDAQ: PHVS), highlighting a strong near-term sentiment moving towards a long-term positive bias. It outlines three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and specific entry, target, and stop-loss …

Savara Inc. (SVRA) Slips 2.79% as Shares Test Key Support at $5.29 - Revenue Weighted

Earnings Flash (PHVS) Pharvaris Posts Q2 Loss 0.70 Euro a Share

Pharvaris (PHVS) boosts cash to €318M as deucrictibant nears key data and FDA date

Harvard Ave Acquisition Ord Shs Class A (HAVA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Pharvaris Reports Q2 2026 Results and Updates on Deucrictibant Development, Regulatory Progress and Financial Position

Pharvaris reported its Q2 2026 financial results, with cash and cash equivalents of €318 million, providing a financial runway into 2028. The company is advancing deucrictibant for bradykinin-mediated angioedema, with topline data from the pivotal Phase 3 CHAPTER-3 study expected in Q3 2026, and …

The Manufacturers Life Insurance Company Sells 833,712 Shares of Varonis Systems, Inc. $VRNS

The Manufacturers Life Insurance Company significantly reduced its stake in Varonis Systems, Inc. (NASDAQ:VRNS) by selling 833,712 shares, decreasing its holdings by 93.9% to 54,001 shares. Despite this large sale, institutional investors still hold 95.65% of the company's stock. Varonis reported strong quarterly revenue …

Pharvaris N.V. $PHVS Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company significantly reduced its stake in Pharvaris N.V. by 44.7% in Q1 2026, selling 35,695 shares. Despite this, analysts maintain a "Moderate Buy" rating with an average price target of $50.08, while company insiders have recently sold a substantial number …

Pharvaris (PHVS) Earnings Date and Reports 2026

Tvardi Therapeutics (TVRD) Holds Ground at $1.77 Amid Cautious Biotech Sentiment - Bullish Pattern Stocks

Varroc Engineering targets ₹20,000 crore revenue by FY31, sees 20-25% FY27 growth

Harvard Bioscience Releases Q2 2026 Financial Results

Harvard Bioscience (HBIO) reported its Q2 2026 financial results, showing a narrower-than-expected adjusted loss of $0.14 per share, beating analyst estimates. Revenue increased by 10.7% to $22.7 million. The company attributes this improvement to steady demand for its laboratory equipment and instruments, reflecting stabilization …

Why is Aardvark Therapeutics stock surging today?

Aardvark Therapeutics stock surged 11.1% in pre-open trading after reporting better-than-expected Q2 2026 financial results, beating EPS estimates by $0.21. The company also announced a stronger cash position extending into late 2027 and ongoing positive discussions with the FDA regarding its ARD-101 program, all …

Harvard Bioscience, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:HBIO) 2026-08-12

Harvard Bioscience, Inc. (HBIO) published its slide deck in conjunction with its Q2 2026 earnings call. The company reported an EPS of -$0.14, beating estimates by $0.07, and revenue of $22.73M, which was an 11.13% year-over-year increase and beat by $1.28M. This article provides …

SAVARA Q2 EPS USD -0.16

The article reports that Savara (SVRA) announced its Q2 Earnings Per Share (EPS) as USD -0.16. This financial figure indicates the company's profitability during the second quarter.

Varex Imaging (VREX) Stock Price Hints Caution After Profit Rebound

Aardvark Therapeutics Q2 Results: Net loss flat at $14.4 million

Aardvark Therapeutics reported a Q2 EPS of $(0.66), surpassing analyst estimates of $(0.91), while its net loss remained flat at $14.4 million compared to the previous year. This performance was largely due to reduced R&D expenses after the halting of ARD-101 trials, although partially …

Form 8K Aardvark Therapeutics Inc For: 11 August By Investing.com

This article reports on the filing of a Form 8K by Aardvark Therapeutics Inc. for August 11. The filing is a standard regulatory disclosure document that companies submit to the SEC. The article lists the company's stock symbol as AARD.

Aardvark Therapeutics (AARD) faces ARD-101 clinical hold but retains $73.9M cash

Aardvark Therapeutics reported a net loss of $14.4 million for Q2 2026 and $36.0 million for the first six months of 2026, driven by R&D and public-company overhead, but maintains $73.9 million in cash, cash equivalents, and short-term investments, expected to fund operations into …

Aardvark Therapeutics (NASDAQ:AARD) Releases Quarterly Earnings Results, Beats Expectations By $0.21 EPS

Aardvark Therapeutics (NASDAQ:AARD) announced its quarterly earnings, reporting a loss of $0.66 per share, which surpassed analyst expectations of a $0.87 loss by $0.21. Despite beating estimates, the company's shares fell by 4.9% to $7.19 during Tuesday trading. Institutional investors have increased their stakes, …

Aardvark to Assess Unblinded Prader-Willi Trial Data in Q3 2026

Aardvark Therapeutics reported its second-quarter 2026 financial results, revealing $73.9 million in cash and short-term investments, which is expected to fund operations into late 2027. The company is currently assessing unblinded Phase 3 HERO and OLE trial data for ARD-101 in Prader-Willi syndrome in …

Aardvark Therapeutics Reports Q2 2026 Results, Updates ARD-101 PWS Program and FDA Discussions

Aardvark Therapeutics announced its Q2 2026 financial results, reporting a net loss of $14.4 million and a cash position of $73.9 million, sufficient to fund operations into late 2027. The company is actively engaging with the FDA to resolve a clinical hold on its …

Aardvark Therapeutics, Inc. Q2 2026: Net loss $14.4M, EPS $(0.66) — 10-Q Summary

Aardvark Therapeutics, Inc. reported a net loss of $14.4 million, or $(0.66) per diluted share, for Q2 2026, consistent with the prior year. Cash and cash equivalents increased to $73.8 million. Clinical trials for ARD-101 and ARD-201 were paused due to cardiac observations, leading …